Richard Kim, Mustapha Tehfe, Petr Kavan, Jorge Chaves, Jeremy S Kortmansky, Eric X Chen, Christopher H Lieu, Lucas Wong, Marwan Fakih, Kristen Spencer, Qing Zhao, Raluca Predoiu, Chenxiang Li, Pierre Leconte, David Adelberg, E Gabriela Chiorean
BACKGROUND: The phase 1b KEYNOTE-651 study evaluated pembrolizumab plus chemotherapy in microsatellite stable or mismatch repair-proficient metastatic colorectal cancer. PATIENTS AND METHODS: Patients with microsatellite stable or mismatch repair-proficient metastatic colorectal cancer received pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, oxaliplatin (previously untreated; cohort B) or 5-fluorouracil, leucovorin, irinotecan (previously treated with fluoropyrimidine plus oxaliplatin; cohort D) every 2 weeks...
April 1, 2024: Clinical Colorectal Cancer